AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03104335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
Study NCT03904485 — intervention group
Intervention type: RADIATION
Intervention: cardiac magnetic resonance(CMR) T2 mapping
Description: T2 value before transplant，3 month and 6month after transplant
Study NCT03100526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Intensive Management
Description: Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues
Study NCT02518529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study NCT04585178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobeat patch
Description: The Biobeat device (BB-613WP) is a class IIa medical device and is a non-invasive patch used for monitoring vital signs in clinical and non-clinical settings. The sensor continuously records the photoplethysmographic waveform that allows the calculation of several physiological parameters: heart rate (HR), SPO2, systolic blood pressure (SBP) and change in SBP, diastolic blood pressure (DBP) and change in DBP, stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), and respiration rate (RR).~Translated with www.DeepL.com/Translator (free version)
Study NCT02171104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD HR-D (High-Risk, Regimen D)
Description: N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
Study NCT03253848 — intervention group
Intervention type: OTHER
Intervention: Best Practice
Description: Discussion between doctors and APL expert
Study NCT03253848 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03253848 — intervention group
Intervention type: PROCEDURE
Intervention: Supportive Care
Description: Receive simplified guidelines and support
Study NCT04123132 — intervention group
Intervention type: OTHER
Intervention: Kinesiophobia
Description: The presence of kinesiofobia in patients with metabolic syndrome
Study NCT01576133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE
Description: Occupational therapy visits plus nursing visits plus handyman repair
Study NCT01576133 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention visits
Description: Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
Study NCT02319122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Intensity Interval Training
Description: See arm description
Study NCT02319122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Progressive Resistance Training
Description: See arm description
Study NCT00042198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Up to 12 weekly, individual, hour-long sessions
Study NCT00042198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Stress Management
Description: Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
Study NCT04928053 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ocytocine dosage and genetic analyse
Description: All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
Study NCT02001623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin (HuMax-TF-ADC)
Study NCT01070888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/Formoterol
Description: Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
Study NCT01070888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol
Description: Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
Study NCT01070888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide 180mcg, 2 puffs twice daily for 2 weeks
Study NCT01070888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 180mcg, 2 puffs twice daily for 2 weeks
Study NCT04152616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental evaluation of posture
Description: After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®).
Study NCT04455516 — intervention group
Intervention type: PROCEDURE
Intervention: Meniscus repair; partial meniscectomy
Description: 69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
Study NCT02452242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: 25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
Study NCT02452242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
Study NCT02091336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: patients treatment
Study NCT02091336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: patients treatment
Study NCT00364286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 50mg Orally twice daily
Study NCT01061424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health worker
Description: community health worker provides home visits for education
Study NCT01061424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mailed information
Description: information on asthma is mailed to the home on the same schedule as the other arm
Study NCT06030713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cord clamping before or after antibiotic (cefazolin) prophylaxis
Study NCT06030713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cord clamping before or after antibiotic (cefazolin) prophylaxis
Study NCT02491554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AC-PC based implantation of ACTIVA INS DBS system
Description: Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
Study NCT02491554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-tractography guided implantation of ACTIVA INS DBS system
Description: MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
Study NCT00470899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drainage of placenta of fetal blood
Study NCT04779892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 100mg/vial
Study NCT04779892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 100mg/vial
Study NCT01886430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Functional electrical stimulation for 10 days
Study NCT01886430 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo electrical stimulation
Description: Placebo electrical stimulation for 10 days
Study NCT02263508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec administered by intratumoral injection
Study NCT02263508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
Study NCT02263508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
Study NCT02263508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intratumoral injection
Study NCT02574026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor tasks
Description: the acquisition of data will be performed in one unique session no drug administration no surgery
Study NCT03521037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib camsylate
Description: In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
Study NCT01750463 — intervention group
Intervention type: OTHER
Intervention: Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor
Description: Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
Study NCT01750463 — intervention group
Intervention type: OTHER
Intervention: Standard Laboratory Blood Draw and Hemoglobin Analysis
Description: Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
Study NCT01773980 — intervention group
Intervention type: OTHER
Intervention: Clinic Intervention
Description: The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
Study NCT01773980 — intervention group
Intervention type: OTHER
Intervention: Patient Intervention
Description: The patient intervention consists of a single 90-minute interactive in-person session.
Study NCT02631148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 2mg controlled release melatonin tablet
Study NCT02631148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet identical to circadin
Study NCT01566708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-Music Therapy immediately
Description: 20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
Study NCT04014582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal Coping Intervention
Description: This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
Study NCT04014582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
Study NCT01682629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing Script
Description: A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration.
Study NCT01566708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-Music Therapy after waiting time
Description: 20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
Study NCT01566708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music-therapeutical stress management coaching
Description: 20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
Study NCT04292054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active intervention
Description: The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
Study NCT04292054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention
Description: The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
Study NCT03737682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ENzyme linked immunity-sorbet assays
Description: Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
Study NCT00873691 — intervention group
Intervention type: DEVICE
Intervention: ICD
Description: Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
Study NCT02894242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Deimos Nasal Pillows Mask
Description: Investigative Nasal Pillows Mask to be used for OSA therapy
Study NCT02130128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungPoint ATV System
Description: The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
Study NCT06246435 — intervention group
Intervention type: OTHER
Intervention: moderate aerobic exercise
Study NCT00842049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Drain (Medtronic lumbar drainage system)
Description: Insertion of lumbar drain to drain cerebrospinal fluid
Study NCT00842049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No lumbar drain
Description: No lumbar drain
Study NCT01465724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
Study NCT03336424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive investigations
Description: Ultrasound, blood tests, urine analysis and culture, uroflowmetry
Study NCT03336424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive investigations
Description: Cystomanometry, pressure flow study, EMG
Study NCT01796782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeloda
Description: Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
Study NCT01796782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QYHJ Granules
Description: 1-4 bags bid , days 1-42, every 6 weeks
Study NCT01191892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Study NCT01191892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT01191892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine hydrochloride
Study NCT01191892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT01191892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Study NCT01191892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of vandetanib tablet
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilutamide
Study NCT00028769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01134562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV injection.
Study NCT01134562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
Study NCT04164381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Study NCT02538614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily
Study NCT02538614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Intravenous administration as a rate-controlled infusion
Study NCT01731301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
Study NCT01731301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon
Description: After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
Study NCT01731301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.